Cargando…
Target-Specific Nanoparticle Polyplex Down-Regulates Mutant Kras to Prevent Pancreatic Carcinogenesis and Halt Tumor Progression
Survival from pancreatic cancer is poor because most cancers are diagnosed in the late stages and there are no therapies to prevent the progression of precancerous pancreatic intraepithelial neoplasms (PanINs). Inhibiting mutant KRAS(G12D), the primary driver mutation in most human pancreatic cancer...
Autores principales: | Smith, Jill P., Chen, Wenqiang, Shivapurkar, Narayan, Gerber, Monica, Tucker, Robin D., Kallakury, Bhaskar, Dasa, Siva Sai Krishna, Kularatne, Ruvanthi N., Stern, Stephan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821664/ https://www.ncbi.nlm.nih.gov/pubmed/36614194 http://dx.doi.org/10.3390/ijms24010752 |
Ejemplares similares
-
Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer
por: Burks, Julian, et al.
Publicado: (2018) -
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
por: Tucker, Robin D., et al.
Publicado: (2019) -
The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery
por: Kularatne, Ruvanthi N., et al.
Publicado: (2022) -
Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome
por: Gay, Martha D., et al.
Publicado: (2022) -
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma
por: Shivapurkar, Narayan, et al.
Publicado: (2023)